Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates and infants, expected to require parenteral nutrition (PN) for 28 days~* Postmenstrual age ≥ 24 weeks~* Birth weight ≥ 750g~* Gastroschisis, duodenal, jejunal or ileal atresia, volvulus, spontaneous intestinal perforation or necrotizing enterocolitis (Bell's stage 2B or higher)~* At least 80% of nutritional needs at baseline received by PN~* Signed and dated informed consent obtained from at least one parent or legal guardian~Exclusion Criteria:~* Conjugated bilirubin \> 0.6 mg/dL~* Any known pre-, intra- or posthepatic complication increasing conjugated bilirubin levels \> 0.6, mg/dL during study participation~* Suspected liver disease or liver damage based on either aspartate aminotransferase (AST), alanine aminotransferase (ALT), or gamma-glutamyl transferase (GGT) exceeding 2.5x upper limit of normal range~* Active bloodstream infection demonstrated by positive blood culture at screening~* Cystic fibrosis~* Meconium ileus~* Serum triglyceride levels \> 250 mg/dL~* Cyanotic congenital heart defect~* Severe renal failure with serum creatinine \> 2.0 mg/dL~* History of shock requiring vasopressors~* Anasarca~* Extracorporeal Membrane Oxygenation (ECMO)~* Known inborn errors of metabolism~* Known congenital viral infection~* Unlikely to survive longer than 28 days~* Known hypersensitivity to fish-, egg-, soya- or peanut protein or to any of the active substances or excipients

- Gender: ALL
- Minimum Age: 0 Weeks
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Smoflipid 20% (Type: EXPERIMENTAL): Smoflipid is a lipid emulsion containing soybean oil, MCTs (medium-chain triglycerides), olive oil, and fish oil. Smoflipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions.
- Intralipid® 20% (Type: ACTIVE_COMPARATOR): Intralipid is a long-chain triglyceride emulsion derived from purified soybean oil and egg yolk phospholipids. Intralipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions.

Based on this trial design, predict the completion outcome and termination type (if applicable).